
|Articles|October 17, 2012
Newer prostate Ca agent shows positive pain outcomes
Recent studies of the oral androgen receptor inhibitor enzalutamide (Xtandi) evaluated the effect of costicosteroid use with the agent as well as its pain-related outcomes in patients with advanced prostate cancer.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC
2
Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring
3
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
4
ACOU085 shows promise for cisplatin-induced hearing loss in patients with testicular cancer
5











